Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D01WZL
|
|||
Former ID |
DIB016992
|
|||
Drug Name |
AVE-8112
|
|||
Synonyms |
AVE8112
Click to Show/Hide
|
|||
Indication | Parkinson disease [ICD-11: 8A00.0; ICD-9: 332] | Phase 1 | [1] | |
Company |
The michael j. fox foundation for parkinson's research; sanofi us
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Phosphodiesterase 4A (PDE4A) | Target Info | Inhibitor | [2] |
Phosphodiesterase 4B (PDE4B) | Target Info | Inhibitor | [2] | |
Phosphodiesterase 4D (PDE4D) | Target Info | Inhibitor | [2] | |
KEGG Pathway | Purine metabolism | |||
cAMP signaling pathway | ||||
Morphine addiction | ||||
NetPath Pathway | IL5 Signaling Pathway | |||
IL2 Signaling Pathway | ||||
Pathwhiz Pathway | Purine Metabolism | |||
Reactome | DARPP-32 events | |||
G alpha (s) signalling events | ||||
WikiPathways | G Protein Signaling Pathways | |||
Myometrial Relaxation and Contraction Pathways | ||||
TSH signaling pathway | ||||
Nuclear Receptors Meta-Pathway | ||||
Opioid Signalling |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01803945) A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease. U.S. National Institutes of Health. | |||
REF 2 | Therapy for Parkinson's Disease: What is in the Pipeline . Neurotherapeutics. 2014 January; 11(1): 24-33. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.